Trial Profile
A Phase I, Open-Label, Randomized, Single-Center, Unblinded, Single-Dose, Five-Way Crossover Study of the Safety and PK Properties of Proellex.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Telapristone (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Repros Therapeutics
- 03 Nov 2008 Status changed from recruiting to completed.
- 26 Sep 2008 New trial record.